| Company Information |
| Address: |
Level 9
2 Kingdom Street
London
W2 6BD
|
Index: |
FTSE 100
FTSE 350
FTSE 350 Higher Yield
FTSE All Share
FTSE TechMark All Share
FTSE Eurotop 300
|
| Tel: |
+44 (0)20 7604 8000
|
Sector: |
Pharmaceuticals
|
| Fax: |
+44 (0)20 7604 8270 |
|
|
| E-Mail: |
IR@astrazeneca.com |
Epic: |
AZN |
| Secretary: |
Adrian Kemp |
|
|
| Registrar: |
Equiniti Ltd
|
Updated: |
15/04/2013 |
News from RSS Feed Thu, 16 May 2013 06:52:36 +0100
AstraZeneca Issues Update on Accelerated Oncology Pipeline in Advance of 2013 ASCO Annual Meeting
First patient enrolled in Phase III clinical trial for moxetumomab pasudotox as a treatment for unresponsive or relapsed hairy cell leukaemia patients.
Olaparib planned to progress to Phase III for platinum-sensitive relapsed ovarian cancer patients with BRCA mutations in 2013.
Selumetinib planned to progress to Phase III for non small cell lung cancer patients with KRAS mutations in 2013.
AstraZeneca today announced that it will be moving three of its cancer compounds forward to Phase III clinical development. As set out at its Investor Day in March, oncology is one of the company’s core therapy areas and accelerating the development of a number of new molecular entities in its pipeline is a strategic priority. |
Company Overview
AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases.
| |
|
|
|
| Dividend History |
|
| Type |
Payment Date |
Dividend |
|
| Interim |
18/03/2013 |
120.5 p |
|
| Interim |
10/09/2012 |
58.1 p |
|
| Interim |
19/03/2012 |
123.6 p |
|
| Interim |
12/09/2011 |
51.9 p |
|
| Interim |
14/03/2011 |
116.7 p |
|
| Interim |
13/09/2010 |
44.9 p |
|
| Interim |
15/03/2010 |
105.4 p |
|
| Interim |
14/09/2009 |
36 p |
|
| Interim |
14/09/2009 |
0.59 c |
USD |
| Interim |
14/09/2009 |
27.8 p |
|
| Interim |
16/03/2009 |
104.8 p |
|
| Interim |
15/09/2008 |
27.8 p |
|
| Interim |
17/03/2008 |
67.7 p |
|
| Interim |
17/09/2007 |
25.3 p |
|
| Interim |
19/03/2007 |
63 p |
|
| Interim |
18/09/2006 |
26.6 p |
|
| Interim |
20/03/2006 |
51.8 p |
|
| Interim |
19/09/2005 |
21.9 p |
|
| Interim |
21/03/2005 |
34.3 p |
|
| Interim |
20/09/2004 |
16 p |
|
| Interim |
6/04/2004 |
29.4 p |
|
| Interim |
6/10/2003 |
15.9 p |
|
| Interim |
7/04/2003 |
28.5 p |
|
| Interim |
7/10/2002 |
14.7 p |
|
| Interim |
8/04/2002 |
33.2 p |
|
| Interim |
5/10/2001 |
16.1 p |
|
| Interim |
9/04/2001 |
32.1 p |
|
| Interim |
23/10/2000 |
15.3 p |
|
| Interim |
17/04/2000 |
29.1 p |
|
| Interim |
25/10/1999 |
14.2 p |
|
|
| |
|
|
| Future Events |
|
| Event |
Date |
|
| Interim Results |
1/08/2013 |
|
| Quarterly Results |
31/10/2013 |
|
|
News from RSS Feed Thu, 16 May 2013 06:52:36 +0100
AstraZeneca Issues Update on Accelerated Oncology Pipeline in Advance of 2013 ASCO Annual Meeting
First patient enrolled in Phase III clinical trial for moxetumomab pasudotox as a treatment for unresponsive or relapsed hairy cell leukaemia patients.
Olaparib planned to progress to Phase III for platinum-sensitive relapsed ovarian cancer patients with BRCA mutations in 2013.
Selumetinib planned to progress to Phase III for non small cell lung cancer patients with KRAS mutations in 2013.
AstraZeneca today announced that it will be moving three of its cancer compounds forward to Phase III clinical development. As set out at its Investor Day in March, oncology is one of the company’s core therapy areas and accelerating the development of a number of new molecular entities in its pipeline is a strategic priority. | Mon, 29 Apr 2013 07:00:00 +0100
Taskforce meets to begin planning for future of Alderley Park
The taskforce set up to assure the future of the Alderley Park site in Cheshire held its first meeting on Friday, attended by George Osborne MP. | Thu, 25 Apr 2013 07:00:00 +0100
AstraZeneca PLC first quarter results 2013
Pascal Soriot, Chief Executive Officer, commenting on the results, said: "As anticipated, the first quarter performance reflects the loss of exclusivity for several large products. We remain focused on our strategic priorities of returning to growth and achieving scientific leadership. Brilinta, the diabetes franchise, Emerging Markets, Japan and our Respiratory products have all made good progress and we continued to invest in distinctive science that will advance our knowledge of disease physiology and help to identify new drug targets." | Mon, 22 Apr 2013 08:00:00 +0100
AstraZeneca and BIND Therapeutics announce worldwide development and commercialisation agreement for cancer nanomedicine
AstraZeneca and BIND Therapeutics announced today that they have entered into a strategic collaboration to develop and commercialise an Accurin™, a targeted and programmable cancer nanomedicine from BIND’s Medicinal Nanoengineering platform, based on a molecularly targeted kinase inhibitor developed and owned by AstraZeneca. | Fri, 5 Apr 2013 07:00:00 +0100
AstraZeneca announces top-line results from OSKIRA-1 Phase III study of fostamatinib in rheumatoid arthritis
AstraZeneca today announced top-line results of OSKIRA-1, a Phase III study to assess the efficacy and safety of fostamatinib, the first oral spleen tyrosine kinase (SYK) inhibitor in development for rheumatoid arthritis (RA). OSKIRA-1 had two primary endpoints: assessing signs and symptoms of RA as measured by ACR20 response rates, and an X-ray endpoint known as mTSS (modified Total Sharp Score). | Wed, 3 Apr 2013 08:00:00 +0100
MedImmune, AstraZeneca’s biologics arm, acquires AlphaCore Pharma
AstraZeneca today announced that MedImmune, its global biologics research and development arm, has acquired AlphaCore Pharma, an Ann Arbor, Michigan-based biotechnology company focused on the development of ACP-501, a recombinant human lecithin-cholesterol acyltransferase (LCAT) enzyme. | Tue, 2 Apr 2013 07:00:00 +0100
US District Court rules one PULMICORT RESPULES® (Budesonide Inhalation Suspension) patent invalid and another patent not infringed
AstraZeneca today announced that the United States District Court for the District of New Jersey ruled that AstraZeneca’s US Patent No. 6,598,603 (“the ‘603 patent”), protecting PULMICORT RESPULES in the US, is invalid. The Court further ruled that the generic defendants involved in the litigation do not infringe AstraZeneca’s second patent, US Patent No. 7,524,834 (“the ‘834 patent”). | Mon, 25 Mar 2013 07:00:00 +0000
AstraZeneca settles litigation over CRESTOR patent
AstraZeneca today announced that it has entered into a settlement agreement in its US patent infringement litigation against Watson Laboratories, Inc., Actavis, Inc. (formerly known as Watson Pharmaceuticals, Inc.), and EGIS Pharmaceuticals regarding Watson’s proposed rosuvastatin zinc product. Watson, a successor of Cobalt, also agreed not to further appeal a decision by the U.S. Court of Appeals for the Federal Circuit that upheld the validity and enforceability of the CRESTOR® (rosuvastatin calcium) substance patent. Shionogi is also a party to the settlement agreement. | Thu, 21 Mar 2013 12:00:00 +0000
AstraZeneca appoints Marc Dunoyer as Executive Vice President, Global Portfolio & Product Strategy
AstraZeneca today announced that Marc Dunoyer is to join the company in the newly created role of Executive Vice President, Global Portfolio & Product Strategy. |
 |
|
|
